

# US Regulatory Affairs A Comprehensive Review of Regulatory Procedures for INDs in the US

16-17 October 2017 Holiday Inn London Kensington Forum, UK

#### **OVERVIEW**

As drug development becomes a global process, have you had questions about US Regulatory requirements? Do you wonder why your US colleagues ask for certain documents or information?

This course will focus on drug and biologic products; the regulatory process for devices or multisourced (generic) products will not be addressed.

#### LEARNING OBJECTIVES

At the conclusion of this course, participants will be able to:

- Define the key principles and processes used by the US Food and Drug Administration (FDA) in regulatory submission and approval
- Define official regulatory policies and other issues pertinent to a successful US regulatory strategy
- Describe key differences between US and EU regulatory requirements
- · Recognise FDA oversight and processes during the post-approval phase
- Interact appropriately with the FDA during all phases of drug development

Participants will complete a knowledge check at the end of the course and will be provided with feedback to ensure learning objectives are attained.

#### **KEY TOPICS**

- Regulation of drugs and biologics: The basics
- Overview of the FDA
- · Regulatory requirements for drug development and approval
- Interactions with FDA
- The IND A general introduction
- The IND In detail
- IND Amendments and maintenance
- Procedures for reporting Adverse Events (AEs) that occur during clinical investigations

## WHO WILL ATTEND

This course is specifically designed for persons with a background in pre-clinical research (e.g., pharmacology, toxicology, and drug metabolism), clinical research, quality assurance or academia, with novice to intermediate experience in Regulatory Affairs, who need knowledge of the US regulatory processes.

This course will also enhance understanding and be beneficial to persons who work in clinical research, data management, biostatistics, basic research, project management and marketing, etc.

DIA Europe, Middle East & Africa also welcomes attendance by regulatory agency staff members.

# FACULTY

Michael R. Hamrell Course Director President, MORIAH Consultants, USA

Carol H. Danielson President, Regulatory Advantage, USA

### SPECIAL OFFER

Register for both Comprehensive Review of Regulatory Procedures in the US training courses and save up to EUR 765!

See registration form on the back for details.



# **ONLINE BEFORE THE COURSE**

### SESSION 1

### INTRODUCTION TO REGULATION OF DRUGS AND BIOLOGICS

- Why do governments regulate drugs and biologics?
- Food and Drug Administration Amendments Act of 2007 (FDAAA)
- Role of FDA and other health regulatory agencies
- What is a regulatory strategy?
- Key definitions

#### SESSION 2

#### THE DRUG DEVELOPMENT PROCESS: AN OVERVIEW

## DAY 1

### 07:30 REGISTRATION

08:00 WELCOME AND INTRODUCTION

#### 08:30 SESSION 1

#### THE IND - A GENERAL INTRODUCTION

Carol Danielson

- What is an IND?
- When is an IND required/not required?
- Types of INDs

## 09:00 SESSION 2

# THE IND IN DETAIL - MODULES 1, 2, & 5

Michael Hamrell

- IND ITEM: Form FDA 1571
- IND ITEM: Table of contents
- IND ITEM: Introductory statement
- IND ITEM: General investigation plan
- IND ITEM: Investigator's brochure
- IND ITEM: Protocols

#### 09:45 COFFEE BREAK

#### 10:00 SESSION 3

#### SPECIAL TOPICS FOR CLINICAL RESEARCH UNDER AN IND Michael Hamrell

- Adequate and well-controlled trials
- Foreign clinical trials
- Surrogate endpoints
- Disease-specific guidance as resources
- Changes in the investigational drug in phases 2-3
- The Animal rule
- Financial disclosure by clinical investigators

# 11:15 SESSION 4

# IND IN DETAIL - MODULE 3

Michael Hamrell

Chemistry, manufacturing and controls (CMC) – Quality Section

# 12:00 LUNCH

#### 13:00 SESSION 5

## IND IN DETAIL - MODULES 4 & 5

Carol Danielson

- IND item: Non-clinical pharmacology and toxicology Safety Section
- IND item: Previous human experience
- IND item: Additional information

## 13:45 SESSION 6

#### IND IN DETAIL - ADDITIONAL TOPICS

#### Michael Hamrell

- Additional requirements for biologics and biotechnology-derived products
- Assembly and submission of an original IND

#### 14:15 SESSION 7

#### FDA'S ACTIONS ON THE ORIGINAL IND & FUTURE AMENDMENTS Carol Danielson

- FDA's review on an IND
- Clinical Holds: Basis for imposition and process for removal
- Administrative actions

#### 14:45 COFFEE BREAK

#### 15:00 SESSION 8

#### ACTIVITIES AND SUBMISSIONS AFTER THE ORIGINAL IND Michael Hamrell

- Amendments to the IND
- Annual reports
- Non-standard INDs
- IND administrative actions

#### 16:00 SESSION 9

#### IND AMENDMENT WORKSHOP

Michael Hamrell

#### 17:00 NETWORKING RECEPTION

18:00 END OF THE DAY

# Continuing Education

The Swiss Association of Pharmaceutical Professionals (SwAPP) and the Swiss Society for Pharmaceutical Medicine (SGPM) have accredited this training course with 9.75 credits.

Special rates available for SwAPP and SGPM members.

SwAPP Swiss Association of Pharmaceutoal Professionate

Unless otherwise disclosed, DIA acknowledges that the statements made by speakers are their own opinion and not necessarily that of the organisation they represent, or that of the DIA. Speakers and agenda are subject to change without notice. Recording during DIA sessions is strictly prohibited without prior written consent from DIA.

# DAY 2

#### 08:30 SESSION 10

#### SPECIAL REGULATORY CONSIDERATIONS FOR DEVELOPMENT Carol Danielson

Special Protocol Assessment

- Special Development Pathways
- a. Subpart E (expedited drug development)
- b. Subpart H (accelerated approval)
- c. Fast Track
- d. New Pathways under FDASIA i. Breakthrough Therapy
  - ii. Qualified Infectious Disease Product
- e. Orphan Products

### 09:45 SESSION 11

## **REPORTING ADVERSE EVENTS (AES) DURING CLINICAL TRIALS** *Michael Hamrell*

- Definitions of terms
- IND safety reports
- IND annual reports Safety information/DSUR
- Termination of studies for safety reasons

## 10:45 COFFEE BREAK

#### 11:00 SESSION 12

# THE FDA AND RISK MANAGEMENT

Carol Danielson

- Pre-marketing risk assessment
- Post-marketing risk assessment
- Risk evaluation and mitigation strategies

12:00 LUNCH & END OF TRAINING COURSE

# Group Discounts

Register 3 individuals from the same company and receive a 50% discount for a 4th! All 4 individuals must register and prepay at the same time without exception. DIA will apply the value of the lowest applicable fee to this discounted registration; it does NOT include fees for optional events or DIA membership. You may substitute group participants of the same membership status at any time; however, administrative fees may be incurred.

Group registration is not available online and only available for the industry rate.

To take advantage of this offer, please print the registration form for each of the four registrants from your company. Include the names of all four group registrants on each of the forms and return them together to DIA.

For groups of 5 or more individuals, please contact <u>EMEA@DIAglobal.org</u> for a custom group rate.

# Training Course Venue

## Holiday Inn London Kensington Forum

97 Cromwell Road London, SW7 4DN Tel: +44 871 942 9100 www.hikensingtonforumhotel.co.uk

www.hikensingtonforumhotel.co.uk DIA has blocked a limited number of hotel

rooms for the course participants from 15 to 18 October 2017 at the rate of GBP 160.00 per standard double room for single use per night including full English breakfast, taxes and service fee.

In order to book a hotel room, please contact the hotel directly and quote the booking reference "DIA/PW3".

The room rate is available until 15 September 2017 or until the room block is sold-out, whichever comes first.

#### HOW TO GET THERE

From Heathrow Airport take the London Underground Victoria line and get off at Gloucester Road. The hotel is located within 3 min walking distance from the station.

# About DIA

DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators, and influencers to exchange knowledge and collaborate in an impartial setting. DIA's network creates unparalleled opportunities for exchange of knowledge and has the inter-disciplinary experience to prepare for future developments.

The dedicated efforts of DIA staff, members and speakers enable DIA to provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials. DIA is a global community representing thousands of stakeholders working together to bring safe and effective products to patients.

DIA is an independent, non-profit organisation has its Global Center in Washington, DC, USA with the European office in Basel, Switzerland, and additional regional offices in Horsham, Pennsylvania, USA; Tokyo, Japan; Mumbai, India; and Beijing, China

Follow @DrugInfoAssn





# **REGISTRATION FORM**

Comprehensive Overview of Regulatory Procedures for INDs in the US #17554 16-17 October 2017 | Holiday Inn London Kensington Forum | London, UK

#### **REGISTRATION FEES**

Registration fee includes refreshment breaks, lunch on the 1st day of the course and electronic access to training course material. Please note that the full amount must be received by DIA by commencement of the course to get the electronic access to the material. Please check:

FEES	MEMBER	NON-MEMBER
INDUSTRY	€ 1′240.00 □	€ 1'395.00 🗖
ACADEMIA/CHARITABLE/GOVERNMENT/NON-PROFIT (FULL-TIME)	€ 620.00 🗖	€ 775.00 🗖
I would like register for the Comprehensive Overview of Regulatory Procedures for INDs in the US #17554 (16-17 October 2017) AND the Comprehensive Overview of Regulatory Procedures for NDAs in the US #17555 (17-18 October 2017) courses to benefit from a		

combo discount.		
INDUSTRY	€ 1'870.00 🗖	€ 2'025.00 🗖
Join DIA now to qualify for the member rate	€ 155.00 🗖	

If DIA cannot verify your membership upon receipt of registration form, you will be charged the non-member fee.

# Please note that the full amount must be received by DIA by commencement of the course to get the electronic access to the material.

The DIA Europe, Middle East & Africa Contact Centre Team will be pleased to assist you with your registration from Monday to Friday between 08:00 and 17:00 CET. Tel. :+41 61 225 51 51 Fax: +41 61 225 51 52

Email: EMEA@DIAglobal.org Mail: DIA Europe, Middle East & Africa, Küchengasse 16, 4051 Basel, Switzerland Web: www.DIAglobal.org

#### CANCELLATION POLICY

All cancellations must be made in writing and be received at the DIA Europe, Middle East and Africa office four weeks prior to the event start date. Cancellations are subject to an administrative fee:

- Industry (Member/Non-member) € 200.00
- Academia/Charitable/Government/Non-profit
- (Full-time) (Member/Non-member) € 100.00

If you do not cancel four weeks prior to the event start date and do not attend, you will be responsible for the full registration fee.

DIA reserves the right to alter the venue and dates if necessary. If an event is cancelled or postponed, DIA is not responsible for airfare, hotel or other costs incurred by registered attendees. Registered attendees are responsible for cancelling their own hotel and travel reservations.

#### **TRANSFER POLICY**

You may transfer your registration to a colleague prior to the start of the event but membership is not transferable. Substitute attendees will be responsible for the nonmember fee, if applicable. Please notify the DIA office of any such substitutions as soon as possible.

#### PHOTOGRAPHY POLICY

By attending the event, you give permission for images of you, captured during the conference through video, photo, and/or digital camera, to be used by DIA in promotional materials, publications, and website and waive any and all rights including but not limited to compensation or ownership.

ATTENDEE DETAILS	PAYMENT METHODS	
Please complete in block capital letters or attach the attendee's business card here.	Credit cards: Payments by VISA, Mastercard or AMEX can be made by completing the details below. Please note that other types of credit card cannot be accepted.	
Prof Dr Dr Ms Mr	Please charge my VISA MC AMEX	
Last Name	Card N°	
First Name	Exp. Date	
Job Title	Cardholder's Name	
Company		
Address	Bank transfers: When DIA completes your registration, an email will be sent to the address on the registration form with instructions on how to complete the bank transfer. Payments in EURO should be addressed to "Account Holder: DIA." Please include your name, company, Course ID # 17554 as well as the invoice number to ensure correct allocation of your payment.	
Postal Code		
City	Payments must be net of all charges and bank charges must be borne by the payer. If you have not received your confirmation within five working days, please contact DIA Europe, Middle East and Africa.	
Country	By signing below, I confirm that I agree with DIA's Terms and Conditions of booking. These are available from the office or on http://www.diaglobal.org/EUTerms	
Telephone Number Fax Number		
Attendee email required for course material access	Date Signature	

